Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512954 | 1.00 | SLC2A1 (0.40) | SLC2A1KCNH2MTNR1AMTNR1BHIF1A | |
| SCHEMBL4520969 | 0.79 | KCNH2 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL4520967 | 0.79 | KCNH2 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL4499945 | 0.76 | KCNH2 (0.64) | KCNH2 | |
| SCHEMBL4775783 | 0.74 | KCNH2 (0.44) | SLC2A1KCNH2 | |
| SCHEMBL4509808 | 0.73 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL4517432 | 0.73 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL4511732 | 0.70 | KCNH2 (0.53) | SLC2A1KCNH2 | |
| SCHEMBL4520953 | 0.69 | PLAU (0.33) | KCNH2 | |
| SCHEMBL4520946 | 0.69 | PLAU (0.33) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-1891078-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125974-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | SLC2A1 3896/4885KCNH2 1951/4885MTNR1A 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.